Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nasdaq: NNOX) is at the forefront of revolutionizing medical imaging through its cutting-edge nanotechnology. The company is developing the next generation of X-ray emitters that aim to bring X-ray imaging into the digital era. Its primary offering, the Nanox System, is a combination of hardware and software designed to enhance and modernize medical imaging.
The key component of this system is the Nanox.ARC, a digital X-ray source that incorporates novel nanotechnology to create detailed 3D images. Accompanying this is the Nanox.CLOUD, a cloud-based software platform that enables the delivery of medical screening as a service.
Nano X Imaging Ltd has made significant strides with its Nanox.AI subsidiary, which focuses on deep-learning medical imaging analytics. This arm of the company leverages AI technology to extract valuable clinical insights from routine medical imaging, facilitating early detection and preventative care pathways for patients globally.
One of the latest achievements includes a remarkable study conducted in partnership with the NHS under the Falls and Fragility Fracture Audit Programme (FFFAP). The study revealed a substantial increase in patient identification for spine fractures using the Nanox.AI algorithm, surpassing the national average by up to sixfold. This success highlights the potential of AI-powered solutions in early diagnosis and improved patient care.
Moreover, Nanox has been actively involved in enhancing its AI capabilities with the development of HealthVCF and its updated version HealthOST, both of which received FDA 510(K) clearance. These AI tools focus on highlighting low bone mineral density and measuring the severity of vertebral compression fractures, thus playing a crucial role in osteoporosis management.
The company also offers Second Opinions, an online medical consultation service through its subsidiary USARAD Holdings INC. This platform integrates Nanox.AI's FDA-cleared AI solutions, allowing patients to gain second opinions from medical experts, promoting early detection and preventive management of chronic conditions.
By providing accessible and affordable diagnostic tools, Nanox's vision is to improve early detection and treatment, thereby enhancing global health outcomes and saving lives. The company's comprehensive ecosystem—including Nanox.ARC, Nanox.AI, Nanox.CLOUD, and USARAD's teleradiology services—creates an innovative network connecting medical imaging solutions from scan to diagnosis.
NANOX IMAGING LTD (NASDAQ: NNOX) appointed Moshe Shtengel as Chief Business Officer on May 2, 2021. With extensive experience in medical business development, Shtengel previously led sales and marketing at Tuttnauer and held key positions at Lumenis and Truphatek. His expertise is expected to enhance Nanox's commercial strategy as they prepare for the launch of their novel Nanox.ARC digital x-ray technology, which has received FDA clearance. The company aims to democratize medical imaging globally.
Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its first quarter 2021 financial results on May 11, 2021, prior to market trading. A conference call will follow at 8:30 AM ET to discuss these results. The company focuses on innovative medical imaging technology, aiming to reduce costs associated with medical imaging systems. Founded by Ran Poliakine, Nano-X intends to collaborate with leading healthcare organizations for affordable imaging services. Further information is available on their website.
Nano-X Imaging Ltd (NASDAQ: NNOX) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC on April 6, 2021. The report includes audited consolidated financial statements, accessible on the SEC's website and Nano-X’s official site. The company emphasizes its mission to democratize healthcare through innovative medical imaging technology, which aims to make imaging services more affordable. Shareholders can request a hard copy of the report free of charge by contacting Investor Relations.
Nanox has announced its Nanox.ARC digital x-ray technology received 510(k) clearance from the FDA, a crucial milestone on its regulatory path in the US. The company plans to start system shipments in late 2021 and aims to deploy 15,000 systems by 2024, expanding accessibility to medical imaging globally. They also intend to submit an additional 510(k) application for their multi-source system in 2021, which could further enhance their commercial offerings.
NANO-X IMAGING LTD (NASDAQ: NNOX) announces that CEO Ran Poliakine will present at the Oppenheimer 31st Annual Virtual Healthcare Conference from March 16-18, 2021. His presentation is scheduled for March 17 at 10:40am ET and will be available via a live webcast. Interested parties can access the presentation through the company’s website, with a replay available for 90 days afterward. Nanox aims to transform medical imaging with affordable solutions, promoting early detection through collaborations with leading healthcare organizations.
Nano-X Imaging Ltd (NASDAQ: NNOX) reported its fourth quarter 2020 results, highlighting the successful demonstration of its Nanox.ARC at the RSNA Virtual Annual Meeting. The company plans to initiate product shipments in Q4 2021. As of Q4 2020, it held $213 million in cash, with no debt. However, the company reported a net loss of $19 million for the quarter and $43.8 million for the year. R&D expenses increased significantly, from $2.7 million in 2019 to $9.2 million, reflecting ongoing development efforts. The company aims to deploy 15,000 Nanox.ARC units globally by 2024.
NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q4 and full year 2020 financial results on March 2, 2021, prior to market opening. A conference call and webcast will follow at 8:30 AM ET. The company focuses on developing an innovative digital X-ray source for medical imaging, aiming to reduce costs and improve access to imaging services. The management's forward-looking statements highlight anticipated risks such as regulatory compliance, technological feasibility, and potential disruptions from public health issues.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced the pricing of its underwritten public offering of 3,091,635 ordinary shares at $62.50 per share, expected to close around February 16, 2021. Notably, the company will not sell any shares nor receive proceeds from this offering, as it involves non-officer, non-director shareholders. Cantor Fitzgerald & Co. and Oppenheimer & Co. are the lead managers for the offering. The SEC has declared the necessary registration effective, with final prospectus copies available through specified channels.
Nano-X Imaging Ltd (NASDAQ: NNOX) announced a proposed underwritten public offering of 2,891,322 ordinary shares by non-officer, non-director shareholders. The company will not receive any proceeds from this sale. The offering is subject to market conditions and comes amid ongoing developments in Nano-X's innovative medical imaging technology. Cantor Fitzgerald & Co. and Oppenheimer & Co. are leading the offering, while a registration statement has been filed but not yet become effective. No assurances are made regarding the timing or completion of the sale.
Nanox Imaging (NNOX) has announced the appointment of three senior executives: Jim Dara as Chief Operating Officer, Ofir Koren as Chief Technology Officer, and Tamar Aharon as Chief Marketing Officer. These additions aim to drive the company's mission to democratize medical imaging. Nanox plans to begin deploying its Nanox.ARC technology in the latter half of 2021, pending regulatory approval. The leadership team is expected to provide diverse expertise, enhancing Nanox's capabilities in launching innovative medical imaging solutions.
FAQ
What is the current stock price of Nano-X Imaging Ltd. (NNOX)?
What is the market cap of Nano-X Imaging Ltd. (NNOX)?
What is NANO-X IMAGING LTD?
What are the main products of NANO-X IMAGING LTD?
What is the Nanox.AI subsidiary?
What recent achievements has Nanox reported?
What is HealthOST?
What is Second Opinions?
How does Nanox aim to improve global health outcomes?
What is the significance of the Nanox.ARC?
How does Nanox.CLOUD contribute to the Nanox System?
What are some of the benefits of using Nanox.AI's solutions?
